The 'Research Use Only' Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day

On April 7, 2026, the FDA published seven warning letters against online peptide sellers — all dated March 31, all issued by the Center for Drug Evaluation and Research, all built around the same legal argument. The sellers had plastered their product pages with "research use only" and "not intended for human consumption" disclaimers. The FDA said that didn't matter. Not when the product pages described appetite suppression, weight loss, and glucose regulation. Not when bacteriostatic water for injection was sitting in the same cart.

If you operate a supplement brand, a med spa, a cosmetic line, or anything adjacent to the peptide economy, this is the enforcement signal you needed to see. The disclaimer era is over.

The seven letters

Here are the firms named in the April 7 cluster, along with what they were selling:

• Pink Pony Peptides (Lovega LLC, Wellington FL) — "GLP-2 TZ," "GLP-3 RT," and Bacteriostatic Water
• Mile High Compounds LLC (Clifton CO) — "GLP-1 SM," "GLP-2 TRZ," "GLP-3 RT," BAC Water, plus a Skool community forum
• Prime Sciences (Scottsdale AZ) — Cagrilintide, "GLP1-R," "GLP1-S," "GLP1-T," Mazdutide, BAC water
• Gram Peptides (Rancho Santa Fe CA) — Retatrutide ("GLP-1-R peptide"), Tirzepatide ("GLP-2 peptide"), Bacteriostatic Water for Injection
• PekCura Labs (Pensacola FL) — "GLP-1-S," "GLP-2-T," "GLP-3-R" (all variations), Bacteriostatic Water
• FormPour (Canton MI) — an eBay store selling "SMGT-GLT-1 Nano Microneedle Patch"
• Guangzhou Huli Technology dba Fantasy Face (Chicago IL) — an eBay store selling "Googeer GLP-1 Weight Control Oral Solution"

The obfuscation is the tell. "GLP-1 SM" is not a real peptide. Neither is "GLP-2 TRZ." These are code names — a thin cosmetic layer over semaglutide, tirzepatide, and retatrutide. The sellers renamed the compounds to disclaim on the label while still marketing the pharmacology.

What the FDA actually said

The clearest statement of the agency's position shows up in the Gram Peptides letter:

"Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use."

The agency then walks through the product pages. For retatrutide, Gram's own copy described "appetite suppression, insulin sensitivity, thermogenesis, and fat-oxidation." For tirzepatide, it described "metabolic regulation," "weight management," and "improved lipid profiles." The page copy was the confession.

Then the FDA points at the bacteriostatic water sitting next to the peptide in the cart:

"The sale of these products together demonstrates that you intend for your 'Bacteriostatic Water for Injection' to be used in combination for injection. Therefore, your 'Bacteriostatic Water for Injection' is a drug."

This is the key move. You can disclaim a molecule. You cannot disclaim the shopping cart.

Why this matters even if you don't sell peptides

Two of the seven firms cited — Gram Peptides and Prime Sciences — were selling retatrutide by name. Retatrutide is not approved by the FDA. It remains investigational. Eli Lilly reported the first Phase 3 readout (TRIUMPH-4) in December 2025 and is expected to submit a New Drug Application in late 2026. Consumers buying "Retatrutide" from a peptide website are buying an investigational drug outside any clinical trial. Cagrilintide (Novo Nordisk) and mazdutide (Innovent Biologics) are also investigational.

The broader pattern matters more than the specific molecules. FDA has now used the same playbook three times in five months:

• November 5, 2025: 17 warning letters in one day against online Botox sellers — the "Botox Blitz"
• March 3, 2026: Nearly 30 warning letters against telehealth platforms and compounding pharmacies making false and misleading claims for GLP-1 weight-loss products
• April 7, 2026: 7 warning letters against online "research peptide" vendors

Three enforcement waves, three different channels, one consistent message: if you are moving unapproved drugs to consumers through the internet, the FDA is watching the page copy, the shopping cart, and the adjacent products. A disclaimer is not a shield when everything around it describes a therapeutic use.

The legal theory in plain language

The FDA's authority here isn't new. Under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act, a product becomes a "drug" the moment it is intended to affect the structure or function of the body. Intent is inferred from context — product claims, labeling, accompanying products, how it's marketed and sold. Section 505(a) then makes it illegal to introduce a new drug into interstate commerce without FDA approval.

A "Research Use Only" label does nothing to change intent if the product page says the compound improves glucose response, slows gastric emptying, and reduces appetite. Courts have consistently held that FDA can look past stated intended use to actual intended use. The April 7 letters are a straightforward application of that doctrine. There is nothing novel here except the scale and the speed.

Three patterns worth tracking

First, FDA is publishing these in coordinated clusters. The seven letters were all dated March 31 and all published on the same day. That's not coincidence. It's a deliberate signal — enforcement isn't retail, it's wholesale. One warning letter is a nudge. Seven on a single day is a market message.

Second, the targets are moving from pharmacies to platforms. The March crackdown hit telehealth platforms and licensed compounding facilities. The April crackdown hit websites and eBay stores. Distribution channels the FDA used to leave to state pharmacy boards and the Federal Trade Commission are now squarely inside CDER's active enforcement docket. Expect Amazon Marketplace, Etsy, TikTok Shop, and Meta advertising to follow.

Third, the FDA is reading your product page copy. Every letter names specific claim language — direct quotes from the seller's website. The agency is doing ordinary content review, not some novel AI-powered surveillance. The lesson for any brand operating in the gray zone of supplements, peptides, cosmetics, or wellness: your own marketing copy is the evidence file.

What we're seeing in the data

Policy Canary has tracked 175 FDA warning letters so far in 2026. Forty-three of them touch GLP-1, peptides, compounded semaglutide, tirzepatide, or related compounds — up from 14 in all of 2024. The weekly cadence has tightened too. What used to be a quarterly enforcement rhythm is now a monthly one, sometimes a biweekly one.

If you sell anything that touches this space — research peptides, weight loss supplements, "metabolic support" stacks, compounded injectables, even wellness platforms that list these products — the base rate of warning letter exposure has roughly tripled in eighteen months. That is not a trend to wait out.

What to do about it

If you are a peptide seller: the "research use only" disclaimer is not a defense. Audit your own product pages. Any claim language describing a therapeutic effect on a named pharmaceutical is evidence the FDA will quote back to you in a warning letter. Remove it, remove the accompanying injection supplies, or stop selling the compound.

If you are a supplement or wellness brand: map every product in your catalog against the compounds showing up in FDA enforcement. The next blitz will not warn you before it arrives. Semaglutide analogs today, something else next quarter.

If you are a retailer, marketplace, or ad platform carrying these listings: FDA warning letters are public. Once a seller is named, continued distribution through your platform puts you inside the same enforcement narrative. Review listings against the warning letter record before it becomes a problem.

We built Policy Canary because most brands discover warning letters the way the public does — through a news article, weeks after the FDA published them. That's too late. If you operate in any product category the FDA is actively enforcing against, the question isn't whether you'll see a warning letter about a competitor. It's whether you'll see it in time to matter.

---

Policy Canary monitors the FDA's full enforcement stream — warning letters, recalls, import alerts, guidance, recalls, and safety alerts — and tells you when something touches your specific products. Start monitoring at policycanary.io.

Sources

• Gram Peptides warning letter, MARCS-CMS 721806, March 31, 2026 (FDA)
• Prime Sciences warning letter, MARCS-CMS 721805, March 31, 2026 (FDA)
• Lovega LLC dba Pink Pony Peptides warning letter, MARCS-CMS 721088, March 31, 2026 (FDA)
• Mile High Compounds LLC warning letter, MARCS-CMS 721600, March 31, 2026 (FDA)
• PekCura Labs warning letter, MARCS-CMS 721709, March 31, 2026 (FDA)
• FormPour warning letter, MARCS-CMS 722215, March 31, 2026 (FDA)
• Guangzhou Huli Technology Co., Ltd. dba Fantasy Face warning letter, MARCS-CMS 722228, March 31, 2026 (FDA)
• FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (FDA)
• Eli Lilly retatrutide TRIUMPH-4 Phase 3 readout, December 11, 2025 (Lilly Investor Relations)